✦ LIBER ✦

Interaction between bolus and infusion of octreotide in portal hypertensive rats

✍ Scribed by M. Kaassis; F. Moal; F. Oberti; N. Veal; P. Calès

Book ID: 118568600
Publisher: Elsevier Science
Year: 1998
Tongue: English
Weight: 156 KB
Volume: 28
Category: Article
ISSN: 0168-8278
DOI: 10.1016/s0168-8278(98)80833-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Effects of somatostatin and octreotide o

Effects of somatostatin and octreotide on portal-systemic collaterals in portal hypertensive rats

✍ Hui-Chun Huang; Fa-Yauh Lee; Che-Chang Chan; Full-Young Chang; Sun-Sang Wang; Ha 📂 Article 📅 2002 🏛 Elsevier Science 🌐 English ⚖ 122 KB

Vascular actions of octreotide in the po

Vascular actions of octreotide in the portal hypertensive rat

✍ R. W. Aboud; C. Connolly; P. A. McCormick; J. R. Docherty 📂 Article 📅 1997 🏛 Nature Publishing Group 🌐 English ⚖ 297 KB

Octreotide potentiates PKC-dependent vas

Octreotide potentiates PKC-dependent vasoconstrictors in portal-hypertensive and control rats

✍ Reiner Wiest; Ming–Hung Tsai; Roberto J. Groszmann 📂 Article 📅 2001 🏛 Elsevier Science 🌐 English ⚖ 273 KB

Haemodynamic effects of chronic octreoti

Haemodynamic effects of chronic octreotide and tetrandrine administration in portal hypertensive rats

✍ YI-TSAU HUANG; YUH-REN CHENG; HAN-CHIEH LIN; SU-MEI CHEN† AND CHUANG-YE HONG 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 376 KB

Sustained reduction of portal pressure b

Sustained reduction of portal pressure by administration of octreotide — LAR in portal hypertensive rats

✍ Katerina E. Kotzampassi; Dimitrios J. Koufogiannis; Efthimios E. Eleftheriadis 📂 Article 📅 2000 🏛 Elsevier Science 🌐 English ⚖ 160 KB

Long-term octreotide treatment prevents

Long-term octreotide treatment prevents vascular hyporeactivity in portal-hypertensive rats

✍ C C Sieber; F Lee; R J Groszmann 📂 Article 📅 1996 🏛 John Wiley and Sons 🌐 English ⚖ 210 KB

Chronically portal-hypertensive rats show in vitro vascular hyporeactivity in large part mediated by the endothelium-derived vasodilator nitric oxide. We tested whether long-term octreotide treatment (15 micrograms/kg subcutaneously in 5% D/W, 8-hourly) corrects the in vitro vascular hyporeactivity.